Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)
Enriqueta Felip1, Rafael Rosell21Vall d’Hebron University Hospital, Barcelona, Spain; 2Institut Català d’Oncologia, Hospital Germans Trias i Pujol, Badalona, Barcelona, SpainAbstract: NSCLC accounts for 80% of all cases of lung cancer, which is the leading...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2008-06-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Online Access: | http://www.dovepress.com/pemetrexed-as-second-line-therapy-for-advanced-non-small-cell-lung-can-a1881 |